OR WAIT null SECS
July 27, 2023
Roche will pay up to $2.8 billion for the rights to Alnylam’s RNA-based hypertension therapeutic.
Tarsus Pharmaceuticals’ Xdemvy (lotilaner ophthalmic solutions) is designed to treat Demodex blepharitis by directly targeting Demodex mites.
Janssen has received a positive opinion from the EMA for two novel bispecific antibodies, TALVEY (talquetamab) and TECVAYLI (teclistamab), which the company is developing to treat blood cancer.
MilliporeSigma has invested $25 million to expand its cell culture media production facility in Lenexa, Kan.
The partnership is an extension of the collaboration from AbbVie and Scripps Research that was formed in 2019, according to the press release.
July 25, 2023
The damage to the facility, which produces 8% of US injectable drug consumption, should not significantly affect the current supply.
July 24, 2023
The framework is now expanded beyond COVID-19 vaccines and treatments.
The paper highlights the potential of AI in the medicinal product lifecycle and the approach that developers should take with it.
Sanofi and Recludix Pharma’s deal centers on developing treatments for various immunological and inflammatory diseases.
WuXi STA’s new high-potency injectable line has an annual capacity of 12 million units.